CytomX Therapeutics, Inc.
Here’s whether CytomX Therapeutics, Inc. (CTMX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: strong 1-year return of +25.0%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-6.29% over 10 days); RSI 30 — oversold; 3-month momentum negative (-40.4%). Currently 63.5% off its 52-week high. Score: -5/7.
CTMX is trading below its 200-day MA ($4.02) — a key warning sign the longer-term trend is under pressure. An RSI of 29.5 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +25.0% compares to +24.4% for SPY (beat the market by 0.6%). The current 63.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.